Skip to main content

Becton Dickinson stock price and financials

  • BDX · NYSE
  • Medical devices
  • Health Care Equipment
  • S&P 500
$218.03+1.08%Close 13 Nov 2026
Market value
$59.14B
P/E
62.85
EV / EBITDA
16.93
Beta · 1 year
0.25
Return · 1 year
+44.4%
52-week range$140.11 — $219.78

Share price close 16 Nov 2026

+12.2%1 monthHigh $218.03Low $190.74
$190$200$210$22023 Oct29 Oct4 Nov10 Nov16 Nov
+51.6%6 monthsHigh $218.03Low $140.71
$140$160$180$200$220Q3 FY2026 report filed 6 Aug 20264 Jun2 Jul30 Jul26 Aug23 Sep20 Oct16 Nov
+42.5%year to dateHigh $218.03Low $140.71
$140$160$180$200$220Q1 FY2026 report filed 9 Feb 2026Q2 FY2026 report filed 7 May 2026Q3 FY2026 report filed 6 Aug 202611 Feb30 Mar14 May1 Jul17 Aug1 Oct16 Nov
+43.3%1 yearHigh $218.03Low $140.71
$140$160$180$200$220Q4 FY2025 report filed 25 Nov 2025Q1 FY2026 report filed 9 Feb 2026Q2 FY2026 report filed 7 May 2026Q3 FY2026 report filed 6 Aug 2026Jan 26Mar 26Apr 26Jun 26Aug 26Sep 26Nov 26
+18.3%3 yearsHigh $218.03Low $129.83
$125$150$175$200$225Q4 FY2023 report filed 21 Nov 2023Q1 FY2024 report filed 1 Feb 2024Q2 FY2024 report filed 2 May 2024Q3 FY2024 report filed 1 Aug 2024Q4 FY2024 report filed 27 Nov 2024Q1 FY2025 report filed 6 Feb 2025Q2 FY2025 report filed 1 May 2025Q3 FY2025 report filed 7 Aug 2025Q4 FY2025 report filed 25 Nov 2025Q1 FY2026 report filed 9 Feb 2026Q2 FY2026 report filed 7 May 2026Q3 FY2026 report filed 6 Aug 2026Apr 24Sep 24Feb 25Aug 25Jan 26Jun 26Nov 26
+65.0%10 yearsHigh $221.94Low $126.96
$125$150$175$200$225Apr 18Sep 19Feb 21Jul 22Jan 24Jun 25Nov 26

Quarterly or annual report filed

In one paragraph

Becton Dickinson reported revenue of $21.8 billion for fiscal year 2025 (the twelve months to 30 Sep 2025), up 8.2% from fiscal 2024. Net income was $1.68 billion and diluted earnings per share $5.82.

In its latest reported quarter, the third quarter of fiscal 2026 (the three months to 30 Jun 2026), revenue was $4.98 billion, down 9.5% from a year earlier.

Figures from Becton Dickinson's annual and quarterly reports, compiled and checked by AapWire. Latest report filed 6 Aug 2026.

Against Health Care

Growth
Lower half
Revenue +6.3% a year over five years · 23rd of 37
Profitability
Bottom quarter
Return on invested capital 4.5%, five-year average · 33rd of 38
Balance sheet
Bottom quarter
Net debt 3.6× EBITDA · 32nd of 38
Valuation
Dearer than most
P/E 62.9 · 34th of 36

Among the sector's S&P 500 members with the figure; the longer the bar, the better placed. Debt and P/E rank lower first.

Revenue FY2025
$21.84B+8.2%
Net income
$1.68B−1.6%
Diluted EPS
$5.82−0.7%
Gross margin
45.4%+0.2 pts
Free cash flow
$2.67B−13.1%
Net debt
$19.44B+3.7%

Fiscal 2025 against fiscal 2024; bars show the last 10 fiscal years; net debt is borrowings and operating lease liabilities less cash and short-term investments at the year end.

Revenue and net income fiscal 2016–2025

  • Revenue
  • Net income
$0$5B$10B$15B$20B$25BRevenue, FY16: $12.48BNet income, FY16: $976MFY16Revenue, FY17: $12.09BNet income, FY17: $1.1BFY17Revenue, FY18: $15.98BNet income, FY18: $311MFY18Revenue, FY19: $17.29BNet income, FY19: $1.23BFY19Revenue, FY20: $16.07BNet income, FY20: $874MFY20Revenue, FY21: $19.13BNet income, FY21: $2.09BFY21Revenue, FY22: $18.87BNet income, FY22: $1.78BFY22Revenue, FY23: $19.37BNet income, FY23: $1.48BFY23Revenue, FY24: $20.18BNet income, FY24: $1.71BFY24Revenue, FY25: $21.84BNet income, FY25: $1.68BFY25

Latest quarter · Q3 FY2026 to 30 Jun 2026, filed 6 Aug 2026 · Full results →

Revenue
$4.98B−9.5% on a year
Gross margin
46.5%−1.4 pts on a year
Operating income
$663.0M−24.8% on a year
Net income
$377.0M−34.3% on a year
Diluted EPS
$1.37−31.5% on a year
Free cash flow
$508.0M−51.8% on a year

Comparable companies All of Health Care →

Becton Dickinson beside the other S&P 500 members in Health Care Equipment, by market value.

Becton Dickinson and comparable companies
CompanyMarket valueDay1 yearRevenue growthNet marginP/E
Becton DickinsonBDX$59.14B+1.1%+44.4%−2.6%4.5%62.9
Abbott LaboratoriesABT$188.1B+1.2%−15.8%+10.0%9.7%40.0
Intuitive SurgicalISRG$152.6B+0.8%−22.5%+20.5%25.5%51.6
Boston ScientificBSX$63.86B+0.3%−57.4%+8.9%16.6%18.2
Edwards LifesciencesEW$61.47B+1.3%+25.2%+13.4%15.3%60.2
Idexx LaboratoriesIDXX$55.78B+0.9%−1.3%+11.9%25.4%47.2
GE HealthCareGEHC$37.71B+1.4%+10.7%+6.9%10.0%17.5

Market value and moves at the latest close. Revenue growth compares the last twelve months with the twelve before; net margin and P/E over the last twelve months; P/E is left blank where earnings are negative.

Margins fiscal 2016–2025

  • Gross
  • Operating
  • Net
0%20%40%60%45.4%11.8%7.7%FY16FY19FY22FY25

Becton Dickinson revenue by segment, product and region

Fiscal years, as the company cuts its revenue in its annual reports; the change on a year under each figure. A change is left out from a loss, from a sliver of revenue, or across a change in how the company reports.

By segment

Becton Dickinson revenue by segment, by fiscal year
RevenueFY 2021FY 2022FY 2023FY 2024FY 2025
Medical$8.36B$8.84B+5.7%$9.50B+7.5%$10.07B+6.0%$11.46B+13.7%
Interventional$4.24B$4.46B+5.3%$4.74B+6.1%$4.98B+5.2%$5.22B+4.8%
Life Sciences (earlier basis)$6.53B$5.56B−14.8%$5.13B−7.7%$5.19B+1.1%$5.17B−0.5%
Total revenue$19.13B$18.87B$19.37B$20.18B$21.84B

By region

Becton Dickinson revenue by region, by fiscal year
RevenueFY 2021FY 2022FY 2023FY 2024FY 2025
United States$10.37B$10.72B+3.4%$11.11B+3.6%$11.66B+4.9%$12.79B+9.7%
EMEA$4.55B$4.04B−11.1%$4.24B+5.0%$4.40B+3.7%$4.73B+7.4%
Greater Asia$3.07B$3.05B−0.7%$2.91B−4.4%$2.91B−0.2%$3.09B+6.4%
Other$1.14B$1.06B−7.4%$1.10B+4.2%$1.21B+9.5%$1.23B+1.7%
Total revenue$19.13B$18.87B$19.37B$20.18B$21.84B

Financial statements

Fiscal years, the latest ending 30 Sep 2025. Amounts in USD. On a narrow screen the table opens on the latest year and scrolls back.

Income statement

Becton Dickinson income statement, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Revenue$12.48B$12.09B$15.98B$17.29B$16.07B$19.13B$18.87B$19.37B$20.18B$21.84B
Revenue growth+21.4%−3.1%+32.2%+8.2%−7.0%+19.0%−1.4%+2.7%+4.2%+8.2%
Gross profit$5.99B$5.94B$7.27B$8.29B$6.80B$8.63B$8.48B$8.17B$9.13B$9.93B
Operating income$1.43B$1.52B$1.51B$1.76B$912.0M$2.25B$2.28B$2.11B$2.40B$2.58B
Net income$976.0M$1.10B$311.0M$1.23B$874.0M$2.09B$1.78B$1.48B$1.71B$1.68B
Diluted EPS$4.49$4.60$0.60$3.94$2.71$6.85$5.88$4.94$5.86$5.82
Gross margin48.0%49.1%45.5%47.9%42.3%45.1%44.9%42.2%45.2%45.4%
Operating margin11.5%12.6%9.4%10.2%5.7%11.8%12.1%10.9%11.9%11.8%
Net margin7.8%9.1%1.9%7.1%5.4%10.9%9.4%7.7%8.4%7.7%

Cash flow

Becton Dickinson cash flow, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Operating cash flow$2.56B$2.55B$2.87B$3.33B$2.94B$4.13B$2.63B$2.99B$3.80B$3.43B
Capital expenditure$693.0M$727.0M$895.0M$957.0M$769.0M$1.19B$973.0M$874.0M$725.0M$760.0M
Free cash flow$1.87B$1.82B$1.97B$2.37B$2.17B$2.93B$1.66B$2.12B$3.07B$2.67B

Balance sheet and shares

Becton Dickinson balance sheet and shares, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Cash and equivalents$1.54B$14.18B$1.14B$536.0M$2.83B$2.28B$1.01B$1.42B$1.72B$567.0M
Total debt$11.55B$18.87B$21.50B$19.39B$18.37B$18.08B$16.57B$16.41B$20.92B$20.02B
Shareholders' equity$7.63B$12.95B$20.99B$21.08B$23.77B$23.68B$25.28B$25.80B$25.89B$25.39B
Diluted shares218M224M265M275M282M292M287M288M291M289M
Dividends per share$2.64$2.92$3.00$3.08$3.16$3.32$3.48$3.64$3.80$4.16

Quarterly figures

The last eight fiscal quarters, the latest ending 30 Jun 2026. Year-on-year growth compares the same quarter of the previous fiscal year.

Becton Dickinson quarterly financial figures
PeriodQ4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Revenue$5.44B$5.17B$5.27B$5.51B$5.89B$5.25B$4.71B$4.98B
Revenue, year on year+6.9%+9.8%+4.5%+10.4%+8.4%+1.6%−10.6%−9.5%
Gross margin45.7%43.2%42.8%47.8%47.5%45.9%45.7%46.5%
Operating income$622.0M$453.0M$546.0M$882.0M$698.0M$552.0M$93.00M$663.0M
Net income$400.0M$303.0M$308.0M$574.0M$493.0M$382.0M−$311.0M$377.0M
Diluted EPS$1.37$1.04$1.07$2.00$1.71$1.34−$1.11$1.37
Free cash flow$882.0M$588.0M$50.00M$1.05B$977.0M$549.0M$473.0M$508.0M

Operating KPIs

The operating figures Becton Dickinson reports beside its statements, then its revenue by product, segment and region, latest period first. Each links to its full history.

Becton Dickinson operating KPIs
KPILatestPeriodChange on a yearRecent periods
Medical revenue$3.2Bquarter to 30 Sep 2025up 11.2%
Medical Essentials revenue$1.7Bquarter to 30 Jun 2026up 4.6%
Interventional revenue$1.4Bquarter to 30 Jun 2026up 6.5%
Life Sciences (earlier basis) revenue$1.3Bquarter to 30 Jun 2025down 0.5%
Connected Care revenue$1.2Bquarter to 30 Jun 2026up 5.0%
BioPharma Systems revenue$670.0Mquarter to 30 Jun 2026up 6.5%
EMEA revenue$4.7Bfiscal year to 30 Sep 2025up 7.4%
Greater Asia revenue$3.1Bfiscal year to 30 Sep 2025up 6.4%
United States revenue$3.1Bquarter to 30 Jun 2026up 6.9%
International revenue$1.9Bquarter to 30 Jun 2026up 3.1%

Method

Each period is read from the report the company filed and checked against accounting identities before it is shown; a figure that does not pass is left blank rather than estimated. Free cash flow is operating cash flow less capital expenditure. Fiscal years follow the company's own calendar. See data and methodology.

The same figures as plain text and JSON.

Questions

What was Becton Dickinson's revenue in fiscal 2025?

$21.8 billion for fiscal year 2025 (the twelve months to 30 Sep 2025), as reported in its annual report.

What was Becton Dickinson's net income in fiscal 2025?

$1.68 billion for fiscal year 2025 (the twelve months to 30 Sep 2025).

What were Becton Dickinson's diluted earnings per share in fiscal 2025?

$5.82 for fiscal year 2025 (the twelve months to 30 Sep 2025).

What is Becton Dickinson's gross margin?

45.4% for fiscal year 2025 (the twelve months to 30 Sep 2025): gross profit divided by revenue.

What is Becton Dickinson's operating margin?

11.8% for fiscal year 2025 (the twelve months to 30 Sep 2025): operating income divided by revenue.

How much free cash flow did Becton Dickinson generate in fiscal 2025?

$2.67 billion for fiscal year 2025 (the twelve months to 30 Sep 2025): operating cash flow less capital expenditure.

Where does Becton Dickinson's revenue come from?

In fiscal 2025, by segment: Medical $11.46B (52%), Interventional $5.22B (24%), Life Sciences (earlier basis) $5.17B (24%), out of $21.84B in all, as stated in its annual report.

In the terminal

Twenty years of Becton Dickinson's figures, KPIs, guidance and a cash-flow valuation.

  • Every report line and operating figure, quarter by quarter
  • Guidance against what was delivered
  • Insider trades and institutional holders
  • Alerts on results, filings and price
See plans